Scholarlink

<p>Prostate cancer (PRAD) is a major malignancy affecting men worldwide. In this study, integrative analysis of public datasets and immunohistochemistry revealed that ACTC1 is upregulated in PRAD. Functional assays showed that ACTC1 overexpression promoted cell proliferation and migration, while its knockdown suppressed malignant behaviors. Consistently, xenograft experiments confirmed that ACTC1 enhanced tumor growth in vivo. Transcriptomic and pathway analyses indicated that ACTC1 regulates immune and inflammatory signaling, with BMP4 identified as a key downstream effector. Moreover, BMP4 overexpression rescued the inhibitory effects of ACTC1 knockdown on proliferation and migration, indicating that ACTC1 drives tumor progression through the BMP4 pathway. Together, our results identify ACTC1 as an oncogenic regulator of prostate cancer progression and suggest the ACTC1–BMP4 axis as a potential therapeutic target.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ACTC1 promotes tumor progression by upregulating BMP4 expression in prostate cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月24日

查看全文
  • Ke Zhang,
  • Ke Wu,
  • Chunchun Zhao,
  • Fei Wang,
  • Chao Liu

摘要

Prostate cancer (PRAD) is a major malignancy affecting men worldwide. In this study, integrative analysis of public datasets and immunohistochemistry revealed that ACTC1 is upregulated in PRAD. Functional assays showed that ACTC1 overexpression promoted cell proliferation and migration, while its knockdown suppressed malignant behaviors. Consistently, xenograft experiments confirmed that ACTC1 enhanced tumor growth in vivo. Transcriptomic and pathway analyses indicated that ACTC1 regulates immune and inflammatory signaling, with BMP4 identified as a key downstream effector. Moreover, BMP4 overexpression rescued the inhibitory effects of ACTC1 knockdown on proliferation and migration, indicating that ACTC1 drives tumor progression through the BMP4 pathway. Together, our results identify ACTC1 as an oncogenic regulator of prostate cancer progression and suggest the ACTC1–BMP4 axis as a potential therapeutic target.